Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration

Survey of Ophthalmology

Volumn 59, Issue 1, 2014, Pages 1-18

  Finger, Robert P ^a,b   Wickremasinghe, Sanjeewa S ^a   Baird, Paul N ^a   Guymer, Robyn H ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Age related macular degeneration; Anti VEGF; Bevacizumab; Ranibizumab; Risk gene; Treatment response

Indexed keywords

AFLIBERCEPT; ANTICOAGULANT AGENT; APOLIPOPROTEIN E; BEVACIZUMAB; COMPLEMENT FACTOR H; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR;

AGE; AGE RELATED MACULOPATHY SUSCEPTIBILITY 2 GENE; APOLIPOPROTEIN E GENE; COMPLEMENT FACTOR H GENE; DRUG RESPONSE; EXUDATIVE MACULAR DEGENERATION; FLUORESCENCE ANGIOGRAPHY; GENE; GENETIC ASSOCIATION; GENOTYPE; HIGH TEMPERATURE REQUIREMENT A 1 GENE; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PHARMACOGENETICS; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; PROGNOSIS; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SUBRETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A GENE; VISUAL ACUITY;

AGE-RELATED MACULAR DEGENERATION; ANTI-VEGF; BEVACIZUMAB; RANIBIZUMAB; RISK GENE; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84890058635     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2013.03.009     Document Type: Review

References (99)

1. Abedi F., Wickremasinghe S., Richardson A.J., et al. Gene variants in the HTRA1 and ARMS2 genes and outcome of anti-VEGF treatment in neovascular AMD. Invest Ophthalmol Vis Sci 2012, 53:2931.
2. Abedi F., Wickremasinghe S., Richardson A.J., et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology 2013, 120:115-121.
3. Amaro M.H., Roller A.B. Intravitreal ranibizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy. Invest Ophthalmol Vis Sci 2011, 52:4004.
4. Arditi A., Cagenello R. On the statistical reliability of letter-chart visual acuity measurements. Invest Ophthalmol Vis Sci 1993, 34:120-129.
5. Attebo K., Mitchell P., Smith W. Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology 1996, 103:357-364.
6. Augood C.A., Vingerling J.R., de Jong P.T., et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol 2006, 124:529-535.
7. Boltz A., Ruibeta M., Jonas J.B., et al. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. Ophthalmology 2012, 119:1615-1620.
8. Boyer D.S., Antoszyk A.N., Awh C.C., et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007, 114:246-252.
9. Bozorg S., Grob S., Hughes G., et al. Genotypic analysis of treatment response to anti-vegf therapy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2011, 52:5242.
10. Brantley M.A., Fang A.M., King J.M., et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007, 114:2168-2173.
11. Bressler N.M., Chang T.S., Suner I.J., et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010, 117. 747-56, e744.
12. Brody B.L., Williams R.A., Thomas R.G., et al. Age-related macular degeneration: a randomized clinical trial of a self-management intervention. Ann Behav Med 1999, 21:322-329.
13. Brody B.L., Gamst A.C., Williams R.A., et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001, 108:1893-1900. discussion 1900-1891.
14. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. NEngl J Med 2006, 355:1432-1444.
15. Brown D.M., Michels M., Kaiser P.K., et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009, 116. 57-65, e55.
16. Byun Y.J., Lee S.J., Koh H.J. Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Jpn J Ophthalmol 2010, 54:571-577.
17. Cardon L.R., Bell J.I. Association study designs for complex diseases. Nat Rev Genet 2001, 2:91-99.
18. Centre for Eye Research Australia: Clear Insight: The Economic Impact and Cost of Vision Loss in Australia 2004, University of Melbourne, Melbourne, Australia.
19. Chamberlain M., Baird P., Dirani M., et al. Unraveling a complex genetic disease: age-related macular degeneration. Surv Ophthalmol 2006, 51:576-586.
20. Chang T.S., Bressler N.M., Fine J.T., et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007, 125:1460-1469.
21. Chen E, Mariani AF, Brown DM: The Superdose Anti-VEGF (SAVE) Trial: 2.0-mg intravitreal ranibizumab for recalcitrant neovascular AMD, Two Year Endpoint Results. ARVO Meeting Abstracts 53:2032,2012.
22. Ciardella A.P., Donsoff I.M., Huang S.J., et al. Polypoidal choroidal vasculopathy. Surv Ophthalmol 2004, 49:25-37.
23. Day S., Acquah K., Lee P.P., et al. Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol 2011, 152:1014-1020.
24. Deangelis M.M., Ji F., Adams S., et al. Alleles in the HtrA serine peptidase 1 gene alter the risk of neovascular age-related macular degeneration. Ophthalmology 2008, 115. 1209-15, e1207.
25. Finger R.P., Fimmers R., Holz F.G., et al. Prevalence and causes of registered blindness in the largest federal state of Germany. Br J Ophthalmol 2011, 95:1061-1067.
26. Finger R.P., Fleckenstein M., Holz F.G., et al. Quality of life in age-related macular degeneration: a review of available vision-specific psychometric tools. Qual Life Res 2008, 17:559-574.
27. Francis P.J. The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: The Lucentis Genotype study. Trans Am Ophthalmol Soc 2011, 109:115-156.
28. Franklin A.J., Shuler M.F., Gupta S., et al. Arms2 In/del polymorphism predicts response to intra vitreal anti-VEGF therapy for choroidal neovascular age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci 2012, 53:6507.
29. Gorin M.B. Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics. Mol Aspects Med 2012, 33:467-486.
30. Guber J., Henrich P.B., Guber I., et al. Predictive factors for poor central retinal thickness response to ranibizumab in wet AMD. Invest Ophthalmol Vis Sci 2012, 53:5155.
31. Haddad S., Chen C.A., Santangelo S.L., et al. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol 2006, 51:316-363.
32. Hagstrom S.A., Ying G.S., Pauer G.J., et al. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2013, 120:593-599.
33. Heier J.S., Brown D.M., Chong V., et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012, 119:2537-2548.
34. Heimes B., Lommatzsch A., Zeimer M., et al. Anti-VEGF therapy of exudative AMD. Prognostic factors for therapy success. Ophthalmologe 2011, 108:124-131.
35. Heimes B., Lommatzsch A., Zeimer M., et al. Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefes Arch Clin Exp Ophthalmol 2008, 246:1229-1234.
36. Holmes K., Roberts O.L., Thomas A.M., et al. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007, 19:2003-2012.
37. Horster R., Ristau T., Sadda S.R., et al. Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2011, 249:645-652.
38. Imai D., Mori K., Horie-Inoue K., et al. CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. JOcul Biol Dis Infor 2010, 3:53-59.
39. Inglehearn C.F., Ali M., Gale R., et al. Improved response to ranibizumab in ex and current smokers with age-related macular degeneration (AMD), but no evidence that CFH, ARMS2/HTRA1 Or VEGF genotypes predict treatment outcome. Invest Ophthalmol Vis Sci 2012, 53:3325.
40. Introini U., Torres Gimeno A., Scotti F., et al. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence. Graefes Arch Clin Exp Ophthalmol 2012, 250:1283-1292.
41. Ivers R.Q., Cumming R.G., Mitchell P., et al. Visual impairment and falls in older adults: the Blue Mountains Eye Study. JAm Geriatr Soc 1998, 46:58-64.
42. Jeng D.J., Sadda S.R. Commonly evaluated optical coherence tomography features are not predictive of number of anti-VEGF injections in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2010, 51:534.
43. Jyothi S., Chowdhury H., Elagouz M., et al. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye 2010, 24:816-824.
44. Kaiser P.K., Brown D.M., Zhang K., et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007, 144:850-857.
45. Kang H., Kang S., Chin H. Pharmacogenetics of complement factor H (Y402H), ARMS2(Loc387715) and Htra1; treatment response of exudative age-related macular degeneration with bevacizumab in Korean population. Invest Ophthalmol Vis Sci 2010, 51:1282.
46. Kang S., Roh Y.J. One-year results of intravitreal ranibizumab for neovascular age-related macular degeneration and clinical responses of various subgroups. Jpn J Ophthalmol 2009, 53:389-395.
47. Kiernan D.F., Hariprasad S.M., Rusu I.M., et al. Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration. Retina 2010, 30:1573-1578.
48. Kitchens J.W., Kassem N., Wood W., et al. Apilot study of pharmacogenetics as a predictor of outcome in patients receiving intravitreal anti-VEGF therapy in age related macular degeneration (AMD). Invest Ophthalmol Vis Sci 2011, 52:5259.
49. Kloeckener-Gruissem B., Barthelmes D., Labs S., et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011, 52:4694-4702.
50. Kloeckener-Gruissem B., Menghini M., Sutter F., et al. Long-term studies on the anti-VEGF treatment success in age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci 2012, 53:5168.
51. Kolb S., Menghini M., Barthelmes D., et al. The predictive value of OCT characteristics for the visual outcome in neovascular AMD. Klinische Monatsblatter Fur Augenheilkunde 2012, 229:343-347.
52. Kovach J.L., Agarwal A., Cade W., et al. The role of genetics and smoking in response to anti-VEGF therapy for wet AMD. Invest Ophthalmol Vis Sci 2011, 52:5231.
53. Lad E.M., Grunwald L., Mettu P.S., et al. Lesion morphology on indocyanine green angiography in age-related macular degeneration with classic choroidal neovascular membrane: implications for response to anti-VEGF treatment. Invest Ophthalmol Vis Sci 2012, 53:5161.
54. Lalwani G.A., Rosenfeld P.J., Fung A.E., et al. Avariable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009, 148. 43-58, e41.
55. Lee A.Y., Raya A.K., Kymes S.M., et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Opthalmol 2009, 93:610-613.
56. Lee S., Jilani S.M., Nikolova G.V., et al. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. JCell Biol 2005, 169:681-691.
57. Lee S.J., Koh H.J. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology 2011, 118:101-110.
58. Levine J.P., Marcus I., Sorenson J.A., et al. Macular hemorrhage in neovascular age-related macular degeneration after stabilization with antiangiogenic therapy. Retina 2009, 29:1074-1079.
59. Levy J., Shneck M., Rosen S., et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol 2009, 29:349-357.
60. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
61. Lim J.H., Wickremasinghe S.S., Xie J., et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol 2012, 153:678-686. e671-2.
62. Lux A., Llacer H., Heussen F.M., et al. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Opthalmol 2007, 91:1318-1322.
63. Mackenzie P.J., Chang T.S., Scott I.U., et al. Assessment of vision-related function in patients with age-related macular degeneration. Ophthalmology 2002, 109:720-729.
64. Mariani A., Deli A., Ambresin A., et al. Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2011, 249:1635-1642.
65. Martin D.F., Maguire M.G., Fine S.L., et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012, 119:1388-1398.
66. McKibbin M., Ali M., Bansal S., et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Opthalmol 2012, 96:208-212.
67. Menger J.F., Haubitz I., Keilhauer-Strachwitz C.N. Influence Of AMD-risk factors on the effectiveness of anti-VEGF therapy in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2012, 53:857.
68. Mettu P.S., Crowell S., Shaw J., et al. Neovascular morphology on ICG angiography predicts response to anti-VEGF therapy in eyes with serous pigment epithelial detachments and age-related macular degeneration. Invest Ophthalmol Vis Sci 2012, 53:2654.
69. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
70. Nakata I., Yamashiro K., Nakanishi H., et al. VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration. Jpn J Ophthalmol 2011, 55:435-443.
71. Nischler C., Oberkofler H., Ortner C., et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmologica 2011, 89:e344-e349.
72. Noh D.H., Chang W., Sagong M. The pharmacogenetic association between genetic factors and early response to ranibizumab for exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 2012, 53:3328.
73. Oishi A., Shimozono M., Mandai M., et al. Recovery of photoreceptor outer segments after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2013, 251:435-440.
74. Oishi A., Mandai M., Nishida A., et al. Remission and dropoutrate of anti-VEGF therapy for age-related macular degeneration. Eur J Ophthalmol 2011, 21:777-782.
75. Olsson A.K., Dimberg A., Kreuger J., et al. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006, 7:359-371.
76. Orlin A., Hadley D., Chang W., et al. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 2012, 32:4-9.
77. Park U.-C., Shin J.Y., Kim S.J., et al. Genetic factors associated with early response to intravitreal ranibizumab treatmentin Korean neovascular age-related macular degeneration patients. Invest Ophthalmol Vis Sci 2012, 53:3327.
78. Parrish R.K., Gedde S.J., Scott I.U., et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol 1997, 115:1447-1455.
79. Rein D.B., Zhang P., Wirth K.E., et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006, 124:1754-1760.
80. Rivera A., Fisher S.A., Fritsche L.G., et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet 2005, 14:3227-3236.
81. Rosenfeld P.J., Shapiro H., Tuomi L., et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011, 118:523-530.
82. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. NEngl J Med 2006, 355:1419-1431.
83. Rubin G.S., Bandeen-Roche K., Huang G.H., et al. The association of multiple visual impairments with self-reported visual disability: SEE project. Invest Ophthalmol Vis Sci 2001, 42:64-72.
84. Sabour-Pickett S., Loughman J., Nolan J.M., et al. Prognostic indicators and outcome measures for patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab. Invest Ophthalmol Vis Sci 2012, 53:4397.
85. Smailhodzic D., Muther P., Chen J.C., et al. Cumulative effect of risk alleles in CFH, ARMS2 and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 2012, 119:2304-2311.
86. Suner I.J., Yau L., Lai P. HARBOR Study: One-year results of efficacy and safety of 2.0 mg versus 0.5 mg ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. ARVO Meeting Abstracts 2012, 53:3677.
87. Takeda A.L., Colquitt J., Clegg A.J., et al. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol 2007, 91:1177-1182.
88. Tannan A., Li C., Stevens T.S. Predicting treatment outcomes in patients with newly diagnosed exudative age-related macular degeneration based on initial presentation. Invest Ophthalmol Vis Sci 2010, 51:907.
89. Taylor H.R., Pezzullo M.L., Keeffe J.E. The economic impact and cost of visual impairment in Australia. Br J Ophthalmol 2006, 90:272-275.
90. Teper S.J., Nowinska A., Pilat J., et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 2010, 16:2598-2604.
91. Tian J., Qin X., Fang K., et al. Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in theChinese population. Pharmacogenomics 2012, 13:779-787.
92. Tolentino M.J. impact of baseline morphologic factors, visual acuity (VA), and induction on treatment response in the LEVEL Study. Invest Ophthalmol Vis Sci 2010, 51:90. LEVEL Study Group.
93. Vedula S.S., Krzystolik M.G. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2008, 16(2):CD005139.
94. Wang V.M., Rosen R.B., Meyerle C.B., et al. Polymorphic variations affecting response to anti-VEGF therapy in patients with exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 2011, 52:1231.
95. Wickremasinghe S.S., Xie J., Lim J., et al. Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD. Invest Ophthalmol Vis Sci 2011, 52:4072-4079.
96. Wickremasinghe S.S., Xie J., Lim J., et al. Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD. Invest Ophthalmol Vis Sci 2011, 52:4072-4079.
97. Yamashiro K., Tomita K., Tsujikawa A., et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am J Ophthalmol 2012, 154:125-136.
98. Ye X., Wang Y., Cahill H., et al. Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization. Cell 2009, 139:285-298.
99. Ying G.-S., Huang J., Maguire M.G., et al. Baseline predictors of visual acuity response to ranibizumab and bevacizumab in the Comparison of AMD Treatment Trial (CATT). Invest Ophthalmol Vis Sci 2012, 53:3681.